First patient dosed in clinical trial of oral treatment for Parkinson’s
The first patient has been dosed in Mission Therapeutics ’ Phase 1b clinical trial of MTX325, an oral treatment for Parkinson’s disease . With several locations open in the U.K., France, Germany, and Australia, the Phase 1b clinical trial (NCT07630545) is still recruiting up to 36 adults aged 40-75
Source: Parkinson's News Today.